Amylyx Pharmaceuticals, Inc. (AMLX)

Amylyx Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	-	87.37	380.79	22.23	0.29
Revenue Growth (YoY)	-	-77.05%	1612.94%	7700.00%	-56.15%
Cost of Revenue	-	124.63	25.44	2.99	-
Gross Profit	-	-37.26	355.35	19.24	-
Selling, General & Admin	62.89	114.33	188.36	127.13	38.93
Research & Development	90.4	140.29	128.19	93.45	44.04
Other Operating Expenses	-	22.85	-	-	-
Total Operating Expenses	153.29	277.47	316.54	220.58	82.97
Operating Income	-153.29	-314.73	38.8	-201.34	-82.69
Interest Income	9.3	13.81	16.16	4.29	0.04
Other Non-Operating Income (Expense)	-0.7	-1.21	-0.66	-0.55	-5.28
Total Non-Operating Income (Expense)	8.6	12.6	15.5	3.74	-5.24
Pretax Income	-144.69	-302.14	54.3	-197.6	-87.93
Provision for Income Taxes	0.05	-0.39	5.03	0.77	-
Net Income	-144.74	-301.74	49.27	-198.38	-87.93
Net Income to Common	-144.74	-301.74	49.27	-198.38	-87.93
Shares Outstanding (Basic)	95	68	67	58	7
Shares Outstanding (Diluted)	95	68	70	58	7
Shares Change (YoY)	38.78%	-2.64%	19.65%	788.13%	-99.89%
EPS (Basic)	-1.53	-4.43	0.73	-3.39	-13.35
EPS (Diluted)	-1.53	-4.43	0.70	-3.39	-13.35
Free Cash Flow	-123.48	-167.8	10.68	-182.4	-75.15
Free Cash Flow Per Share	-1.31	-2.46	0.15	-3.12	-11.41
Gross Margin	-	-42.65%	93.32%	86.54%	100.00%
Operating Margin	-	-360.22%	10.19%	-905.72%	-29013.33%
Profit Margin	-	-345.36%	12.94%	-892.38%	-30852.98%
FCF Margin	-	-192.06%	2.80%	-820.50%	-26369.12%
EBITDA	-152.77	-313.83	39.89	-200.85	-82.64
EBITDA Margin	-	-359.19%	10.48%	-903.53%	-28995.09%
EBIT	-153.29	-314.73	38.8	-201.34	-82.69
EBIT Margin	-	-360.22%	10.19%	-905.72%	-29013.33%
Effective Tax Rate	-0.03%	0.13%	9.26%	-0.39%	0.00%

Updated Mar 3, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q